Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

D. J. McGrail; P. G. Pilié; N. U. Rashid; L. Voorwerk; M. Slagter; M. Kok; E. Jonasch; M. Khasraw; A. B. Heimberger; N. T. Ueno; R. Ferrarotto; J. T. Chang; S. Y. Lin

doi:10.1016/j.annonc.2022.07.009

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

D. J. McGrail, P. G. Pilié, N. U. Rashid, L. Voorwerk, M. Slagter, M. Kok, E. Jonasch, M. Khasraw, A. B. Heimberger, N. T. Ueno, R. Ferrarotto, J. T. Chang, S. Y. Lin

Research output: Contribution to journal › Letter › peer-review

4 Scopus citations

Original language	English (US)
Pages (from-to)	1204-1206
Number of pages	3
Journal	Annals of Oncology
Volume	33
Issue number	11
DOIs	https://doi.org/10.1016/j.annonc.2022.07.009
State	Published - Nov 2022

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.1016/j.annonc.2022.07.009

Cite this

McGrail, D. J., Pilié, P. G., Rashid, N. U., Voorwerk, L., Slagter, M., Kok, M., Jonasch, E., Khasraw, M., Heimberger, A. B., Ueno, N. T., Ferrarotto, R., Chang, J. T., & Lin, S. Y. (2022). Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. Annals of Oncology, 33(11), 1204-1206. https://doi.org/10.1016/j.annonc.2022.07.009

McGrail, DJ, Pilié, PG, Rashid, NU, Voorwerk, L, Slagter, M, Kok, M, Jonasch, E, Khasraw, M, Heimberger, AB, Ueno, NT, Ferrarotto, R, Chang, JT & Lin, SY 2022, 'Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay', Annals of Oncology, vol. 33, no. 11, pp. 1204-1206. https://doi.org/10.1016/j.annonc.2022.07.009

@article{fdce56927bd74150b98cb9ee02ef8381,

title = "Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay",

author = "McGrail, {D. J.} and Pili{\'e}, {P. G.} and Rashid, {N. U.} and L. Voorwerk and M. Slagter and M. Kok and E. Jonasch and M. Khasraw and Heimberger, {A. B.} and Ueno, {N. T.} and R. Ferrarotto and Chang, {J. T.} and Lin, {S. Y.}",

note = "Funding Information: This work was supported by the National Cancer Institute, United States at the National Institutes of Health, United States [grant number R00CA240689] to DJM. ",

year = "2022",

month = nov,

doi = "10.1016/j.annonc.2022.07.009",

language = "English (US)",

volume = "33",

pages = "1204--1206",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

number = "11",

}

TY - JOUR

T1 - Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

AU - McGrail, D. J.

AU - Pilié, P. G.

AU - Rashid, N. U.

AU - Voorwerk, L.

AU - Slagter, M.

AU - Kok, M.

AU - Jonasch, E.

AU - Khasraw, M.

AU - Heimberger, A. B.

AU - Ueno, N. T.

AU - Ferrarotto, R.

AU - Chang, J. T.

AU - Lin, S. Y.

N1 - Funding Information: This work was supported by the National Cancer Institute, United States at the National Institutes of Health, United States [grant number R00CA240689] to DJM.

PY - 2022/11

Y1 - 2022/11

UR - http://www.scopus.com/inward/record.url?scp=85137368718&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85137368718&partnerID=8YFLogxK

U2 - 10.1016/j.annonc.2022.07.009

DO - 10.1016/j.annonc.2022.07.009

M3 - Letter

C2 - 35926816

AN - SCOPUS:85137368718

SN - 0923-7534

VL - 33

SP - 1204

EP - 1206

JO - Annals of Oncology

JF - Annals of Oncology

IS - 11

ER -

Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this